<SEC-DOCUMENT>0001390478-23-000013.txt : 20230511
<SEC-HEADER>0001390478-23-000013.hdr.sgml : 20230511
<ACCEPTANCE-DATETIME>20230511161623
ACCESSION NUMBER:		0001390478-23-000013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230511
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230511
DATE AS OF CHANGE:		20230511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		23911273

	BUSINESS ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		6462005278

	MAIL ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sls-20230511.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:78dcd3ce-21a0-469b-aee1-3ed1e57b7bb7,g:0a208b56-3e14-4eb3-b5e3-631f9cbfec09,d:2d17031b14a94fe99dc42279a5c3a9b8--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sls-20230511</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF80L2ZyYWc6ZTBiYjM1Mjc2MDNiNDVlMDgyZDhiZWIyZTkxOTBmYmEvdGFibGU6NDhlOGZjN2JhNzNlNDI3Yzk5NTMzMDgwNWJlNjI2YzYvdGFibGVyYW5nZTo0OGU4ZmM3YmE3M2U0MjdjOTk1MzMwODA1YmU2MjZjNl8xLTEtMS0xLTU2OTU3_9faf464b-1a18-4fc3-893b-84d35778f004">0001390478</ix:nonNumeric><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF80L2ZyYWc6ZTBiYjM1Mjc2MDNiNDVlMDgyZDhiZWIyZTkxOTBmYmEvdGFibGU6NDhlOGZjN2JhNzNlNDI3Yzk5NTMzMDgwNWJlNjI2YzYvdGFibGVyYW5nZTo0OGU4ZmM3YmE3M2U0MjdjOTk1MzMwODA1YmU2MjZjNl8yLTEtMS0xLTU2OTU3_5969b188-4bc8-47b2-8efc-ef0816052637">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sls-20230511.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-11</xbrli:startDate><xbrli:endDate>2023-05-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2d17031b14a94fe99dc42279a5c3a9b8_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">UNITED STATES <br/>SECURITIES AND EXCHANGE COMMISSION  <br/>WASHINGTON, D.C. 20549 </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODEy_c075c3ec-be7f-4f41-9656-958e3df2f8f4">8-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CURRENT REPORT<br/>PURSUANT TO SECTION 13 OR 15(d) OF THE <br/>SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yMzQ_77cb147d-948e-4716-9aa3-1ec22d19ff35">May 11, 2023</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODEz_78180409-6cfc-4201-80a0-515de5e37780">SELLAS Life Sciences Group, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18wLTAtMS0xLTU2OTU3_73c1c18a-d8ed-425f-9962-767fa552d625">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18wLTItMS0xLTU2OTU3_5e0073bb-f658-4f9e-86b3-0a956cfc3dd4">001-33958</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18wLTQtMS0xLTU2OTU3_81995cc7-d64c-47ea-afce-2492ec75b11a">20-8099512</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfNQ_91abcf4c-3619-442c-a2a8-ae258707d4d2">7 Times Square</ix:nonNumeric>, <ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfOQ_290e2f26-dab6-4be8-bf5f-a9afc1885d8c">Suite 2503</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfMTI_9d927d60-57a2-4d86-a4eb-395f37d3c98a">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfMTY_82492b20-a4d3-42b8-9bca-8820a3259f44">NY</ix:nonNumeric> <ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfMTk_46370a03-8705-43bc-8115-130458c2e797">10036</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y182LTAtMS0xLTU2OTU3L3RleHRyZWdpb246NDU2NmE0YWQ1OTkzNDVkMzliM2JmNWUzZjJmNmFlY2ZfNTY_e8f491c4-501a-4c13-af1b-f9bd8b40a207">(646)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y182LTAtMS0xLTU2OTU3L3RleHRyZWdpb246NDU2NmE0YWQ1OTkzNDVkMzliM2JmNWUzZjJmNmFlY2ZfNTk_169e8703-6533-4fb2-902e-43726dcc56b7">200-5278</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODE3_a7444ee9-c0de-4e06-a0c1-9558d4c6730a">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR&#160;230.425) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODE5_04cf3cbf-e040-4aae-ad75-3be0eca60f3a">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR&#160;240.14a-12) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODIx_9e30fab0-186f-4ed8-a6a2-f8c824f12652">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR&#160;240.14d-2(b)) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODE1_62a53652-fd02-4739-98e6-1820e7847e87">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR&#160;240.13e-4(c)) </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6YzdjN2ZmZWU3ZGU2NDliM2JmNmJiZmE1OGI3MWRmYmYvdGFibGVyYW5nZTpjN2M3ZmZlZTdkZTY0OWIzYmY2YmJmYTU4YjcxZGZiZl8xLTAtMS0xLTU2OTU3_8a87491e-edb8-4ee9-98fd-7178a1c5020f">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6YzdjN2ZmZWU3ZGU2NDliM2JmNmJiZmE1OGI3MWRmYmYvdGFibGVyYW5nZTpjN2M3ZmZlZTdkZTY0OWIzYmY2YmJmYTU4YjcxZGZiZl8xLTEtMS0xLTU2OTU3_67aa85da-0fd1-4761-be5f-91a27e9e6d8b">SLS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6YzdjN2ZmZWU3ZGU2NDliM2JmNmJiZmE1OGI3MWRmYmYvdGFibGVyYW5nZTpjN2M3ZmZlZTdkZTY0OWIzYmY2YmJmYTU4YjcxZGZiZl8xLTItMS0xLTU2OTU3_424e22a8-f4c6-40b4-adf1-b15148ab51ee">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter). </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODE2_c4fad4d5-7d02-41f9-bab8-34062f2cab9f">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744; </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2023, SELLAS Life Sciences Group, Inc. (&#8220;SELLAS&#8221;) issued a press release (the &#8220;Press Release&#8221;) announcing its financial results for the quarter ended March 31, 2023 and providing a corporate update.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form&#160;8-K&#160;shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form&#160;8-K shall not be incorporated by reference into any filing with the SEC made by SELLAS whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls-202305118xkexhibit991.htm">Press Release dated May 11, 2023</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELLAS Life Sciences Group, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sls-202305118xkexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8e46122e4d4f44afb882c8f0009cc8eb_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:112%">SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results</font></div><div><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 Study of Novel, Highly Selective CDK9 Inhibitor GFH009 Successfully Completed for Patients with Acute Myeloid Leukemia&#59; 94% of Patients Enrolled to Date Alive and Durable Remission in Patient with Acute Myeloid Leukemia &#62; 6 months</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia on Track for Interim Analysis by Late 2023&#47;Early 2024</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) &#8211; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SELLAS Life Sciences Group, Inc. (NASDAQ&#58; SLS) (&#8220;SELLAS&#8217;&#8217; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended March 31, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are pleased with the continued advancement of both our galinpepimut-S (GPS) and GFH009 clinical programs during the first quarter of 2023, which positions us for near-term execution of several key value-driving milestones,&#8221; said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. &#8220;Positive topline data for the patient group with acute myeloid leukemia (AML) from the GFH009 Phase 1 dose-escalation trial in relapsed&#47;refractory myeloid malignancies suggests strong evidence of anti-tumor activity and survival benefit in this group with no significant safety issues. This supports advancement to a Phase 2a trial in patients with AML in combination with azacitidine and venetoclax, which we are initiating this quarter, with topline data expected in Q4 2023.  Last month, the Independent Data Monitoring Committee (IDMC) also recommended that our GPS Phase 3 REGAL study continue without any modifications and is expected to meet again in Q3 to provide further guidance.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Stergiou continued &#8220;The key objectives for us this quarter and next, among others, will include&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the initiation of the GFH009 Phase 2a study in AML patients in combination with azacitadine and venetoclax&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">completion of, and report of, data from the lymphoma patient group from the GFH009 Phase 1 study&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">report of topline data from the GPS investigator-sponsored trial (IST) in malignant pleural mesothelioma (MPM)&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">abstract acceptance of our GPS ovarian cancer data from a major medical gynecological conference&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">3D Medicines participation in the REGAL study&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">meeting of, and feedback from, the IDMC for the REGAL study.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;It was a great pleasure meeting our SELLAS colleagues last month at our Shanghai headquarters where we had a chance to discuss and further strengthen our strategic partnership,&#8221; said John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3D Medicines. &#8220;The blinded pooled analysis of GPS in AML conducted at the end of last year is indeed very exciting and may have the potential to improve AML patients&#8217; quality of life and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">extend survival. We eagerly anticipate joining the REGAL trial very soon and to enroll about 20 patients in China to satisfy Chinese regulatory requirements towards a potential market approval. In addition, we will work together to explore solid tumor indications for GPS by combination with our subcutaneous anti-PD-L1, envafolimab, and other products.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pipeline Update&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Galinpepimut-S (GPS)&#58; Wilms Tumor-1 (WT1) targeting immunotherapeutic</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase 3 REGAL study in AML&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Enrollment continued in the global Phase 3 REGAL registrational clinical trial in patients with AML who have achieved complete remission following second-line salvage therapy (CR2 patients), with interim analysis continuing to be expected to occur in late 2023 or early 2024. The participation of 3D Medicines in the REGAL study through the enrollment of patients from the Greater China territory will trigger milestone payments totaling $13.0 million to SELLAS, which the Company expects to receive by the end of the third quarter of 2023. The IDMC performed a routine, prespecified risk-benefit assessment of unblinded data from the REGAL study in April 2023 and recommended that the trial continue without modifications. The IDMC endorsed all clinical trial initiatives undertaken in REGAL to advance GPS, including the addition of clinical sites in China. The next routine IDMC meeting is scheduled for the third quarter of 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3D Medicines Phase 1 clinical trial in China&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> 3D Medicines continued enrollment in China for their open-label, single-arm, multi-center Phase 1 clinical trial in patients with AML, multiple myeloma, non-Hodgkin&#8217;s lymphoma, or higher-risk myelodysplastic syndrome.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase 1&#47;2 Study in combination with pembrolizumab (Keytruda&#174;) in ovarian cancer&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Top-line data released in November 2022 showed clinical benefit of GPS in combination with pembrolizumab anti-PD-1 therapy in WT1 positive relapsed or refractory platinum resistant advanced metastatic ovarian cancer patients. The study was conducted under a Clinical Trial Collaboration and Supply Agreement with Merck &#38; Co., Inc., Rahway, N.J., USA (known as MSD outside the United States and Canada), and SELLAS plans to present final data at a medical conference during the fourth quarter of 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase 1 Study in combination with nivolumab (Opdivo&#174;) for MPM&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Patient enrollment was completed at the end of 2022 for an investigator sponsored open-label Phase 1 trial for GPS combination therapy with checkpoint inhibitor nivolumab (Opdivo&#174;) for treatment of MPM in patients who were either refractory to or relapsed after at least one line of the standard of care therapy. SELLAS expects to report topline data during the first half of 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase 1 Study in combination with nivolumab (Opdivo&#174;) in ovarian cancer&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Final analysis was published in the peer-reviewed journal Cancers on previously reported data from the Phase 1 clinical trial showing clinical benefit of GPS combination with anti-PD-1 antibody nivolumab (Opdivo&#174;) in patients with relapsed WT1-expressing ovarian cancers (NCT02737787). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">GFH009&#58; highly selective CDK9 inhibitor</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase 1 clinical trial in hematological malignancies&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In the Phase 1 trial of GFH009, dose escalation was successfully completed in the group of patients with AML, while dose escalation continues in the lymphoma group at the highest dose level for that group (75 mg). Positive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">topline data for the group of patients with AML showed evidence of anti-tumor activity increasing with higher doses and no significant safety issues even at the highest dose levels. The recommended Phase 2 dose (RP2D) has been established for AML. SELLAS plans to commence a Phase 2a trial with GFH009 in combination with venetoclax and azacitidine (aza&#47;ven) in patients with AML during the second quarter of 2023 with topline data expected in the fourth quarter of 2023.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate Updates&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Underwritten Public Offering&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> On February 28, 2023, the Company closed an underwritten public offering providing gross proceeds of $20.0 million, before deducting underwriting discounts and commissions and offering expenses.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appointment of Vice President, Head of Regulatory Affairs&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Andrew Elnatan joined the leadership team in January 2023 as Vice President, Regulatory Affairs, CMC and Quality. He brings nearly three decades of global regulatory experience with successful breakthrough therapy designation and global drug approvals.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results for the First Quarter 2023&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Licensing Revenue&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> There was no licensing revenue for the first quarter of 2023, as compared to $1.0 million for the same period in 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenue&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> There was no cost of revenue for the first quarter of 2023, as compared to $0.1 million for the same period in 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D Expenses&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Research and development expenses for the first quarter of 2023 were $7.2 million, compared to $4.6 million for the same period in 2022. The increase was primarily due to the ongoing Phase 3 REGAL clinical trial of GPS in AML patients and the Phase 1 clinical trial of GFH009 in hematological malignancies. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">G&#38;A Expenses&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> General and administrative expenses for the first quarter of 2023 were $4.1 million, as compared to $3.0 million for the same period in 2022. The increase was primarily due to personnel-related expenses due to increased headcount.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Acquired In-Process Research and Development&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> There was no acquired in-process research and development for the first quarter of 2023, compared to $10.0 million for the same period in 2022 from the in-licensing of GFH009. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Net loss was $11.1 million for the first quarter of 2023, or a basic and diluted loss per share of $0.47, compared to a net loss of $16.7 million for the same period in 2022, or a basic and diluted loss per share of $1.05. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Position&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As of March 31, 2023, cash and cash equivalents totaled approximately $23.9 million.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Keytruda</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &#38; Dohme LLC, a subsidiary of Merck &#38; Co., Inc., Rahway, NJ, USA and is not a trademark of SELLAS. Opdivo</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is a registered trademark of Bristol-Myers Squibb Company, New York, NY, USA and is not a trademark of SELLAS. The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">manufacturers of these brands are not affiliated with and do not endorse SELLAS or its products.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About SELLAS Life Sciences Group, Inc.</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS&#8217; lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China. For more information on SELLAS, please visit www.sellaslifesciences.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements. All statements other than statements of historical facts are &#8220;forward-looking statements,&#8221; including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;intend,&#8221; or &#8220;continue&#8221; and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS and GFH009 clinical development programs, clinical data for both GPS and GFH009, plans for further clinical development of GFH009 and the potential for GPS and GFH009 as drug development candidates. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption &#8220;Risk Factors&#8221; in SELLAS&#8217; Annual Report on Form 10-K filed on March 16, 2023 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS&#8217; forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Contact</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bruce Mackle</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Managing Director</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LifeSci Advisors, LLC</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SELLAS&#64;lifesciadvisors.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of licensing revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,174&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,611&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,107&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,024&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,281&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,735&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,281)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,735)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-operating income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-operating income (expense), net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,097)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,744)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Per share information&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.47)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.05)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,547,562&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,897,479&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.766%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,902&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,125&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,020&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,022&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,756&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">874&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,104&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,943&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,099&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,357&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,485&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,286&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development payable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,511&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,515&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">422&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">573&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,935&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,092&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.0001&#160;par value&#59; 5,000,000&#160;shares authorized&#59; Series A convertible preferred stock, 17,500 shares designated&#59; no shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $0.0001&#160;par value&#59; 350,000,000&#160;shares authorized, 28,347,920 and 21,005,405&#160;shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,167&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,753&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191,001)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(179,904)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,169&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,851&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,104&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,943&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sls-20230511.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:78dcd3ce-21a0-469b-aee1-3ed1e57b7bb7,g:0a208b56-3e14-4eb3-b5e3-631f9cbfec09-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sls="http://www.sellaslifesciences.com/20230511" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sellaslifesciences.com/20230511">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20230511_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20230511_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sellaslifesciences.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sls-20230511_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:78dcd3ce-21a0-469b-aee1-3ed1e57b7bb7,g:0a208b56-3e14-4eb3-b5e3-631f9cbfec09-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_c0a1464c-d856-4fdc-aed8-8d2e81a0bf6a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b784f0fb-da08-4eae-9b0d-a13017b31f10_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5855014e-b55a-4627-80c5-f43393d2de7f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5cc48335-b4ba-420b-8ad2-28f8273811f0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_eda4d185-6f7c-4936-9e87-3084bce6f0b6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_56284db1-5899-4a1d-a0f0-96210d1728f9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_e6641323-74a6-4747-9788-85f085c69fbf_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b5ba20ad-30ca-494b-b1f7-5926efd5a410_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_938b614f-027d-4a2c-ad35-8136dbb1c852_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d3ae3736-1c8f-4d3f-af00-c5383598bcb3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_cb506a36-b083-4abc-b5cf-1d5add833a7c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_5e0b851e-5cd7-4d56-9c0b-1242d44c057e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1cda2605-991b-4b96-acd9-49a60e0218c5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3cb375c8-e148-4a2d-baf6-c6880e042d20_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a7c233f1-d4aa-4ed6-9046-b42a4041b52f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_15c906ba-8241-40a3-aa0b-e237d3409e2d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9d6ebd36-2bc3-4443-b2e4-f2764a69e568_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_4e247523-d63c-4281-a7c4-3588a4ae232c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8a4b1678-b569-410e-bf64-116a58b1c40e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_069b1f6a-2cc7-44dd-9fbc-2ad13a5bb60e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f8b4563f-af3a-48b0-aa65-1455fd25ea19_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e7705f0c-3172-4381-be99-a76fd044f9c8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4ab65294-eb69-43a8-8e55-fa599e310d85_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sls-20230511_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:78dcd3ce-21a0-469b-aee1-3ed1e57b7bb7,g:0a208b56-3e14-4eb3-b5e3-631f9cbfec09-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sellaslifesciences.com/role/Cover" xlink:type="simple" xlink:href="sls-20230511.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sellaslifesciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_661696a0-0109-4299-9933-53b2e3fa6885" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_DocumentType_661696a0-0109-4299-9933-53b2e3fa6885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0ba478fb-3d03-4b6d-b289-7afbcb892e73" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_DocumentPeriodEndDate_0ba478fb-3d03-4b6d-b289-7afbcb892e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bd375cef-45d0-40aa-8368-29df1604a4a0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityRegistrantName_bd375cef-45d0-40aa-8368-29df1604a4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b3187d47-2255-41ff-9ebd-9f05fc2d9b35" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b3187d47-2255-41ff-9ebd-9f05fc2d9b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_58edb044-4e52-4bfd-abc8-dee00648ea70" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityFileNumber_58edb044-4e52-4bfd-abc8-dee00648ea70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_82409ffc-3a28-4638-bf72-e7130dca0573" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityTaxIdentificationNumber_82409ffc-3a28-4638-bf72-e7130dca0573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6f714e99-1cdd-466e-9cd7-de661c942696" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityAddressAddressLine1_6f714e99-1cdd-466e-9cd7-de661c942696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_94fd45a9-0105-4ebc-8416-86f8a099f264" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityAddressAddressLine2_94fd45a9-0105-4ebc-8416-86f8a099f264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a6802ec8-bafb-4a2e-89f4-a6e94e2fc4e8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityAddressCityOrTown_a6802ec8-bafb-4a2e-89f4-a6e94e2fc4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_206e3b49-2983-4e70-aaa4-96fbf2d76373" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityAddressStateOrProvince_206e3b49-2983-4e70-aaa4-96fbf2d76373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_37cce264-e326-4617-b21e-3cdf163e1e4b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityAddressPostalZipCode_37cce264-e326-4617-b21e-3cdf163e1e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d96fd472-c1e6-4530-814f-81bd6e572a25" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_CityAreaCode_d96fd472-c1e6-4530-814f-81bd6e572a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_656e72a2-b488-493c-8846-268a8a0f74db" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_LocalPhoneNumber_656e72a2-b488-493c-8846-268a8a0f74db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_3596a9e2-4504-45a5-bfb5-cd8627aab019" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_WrittenCommunications_3596a9e2-4504-45a5-bfb5-cd8627aab019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_42bed12e-1c0e-45de-b982-c538267ab7ea" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_SolicitingMaterial_42bed12e-1c0e-45de-b982-c538267ab7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_32dc2d4d-9768-43ff-b3b7-c9db1b63745c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_PreCommencementTenderOffer_32dc2d4d-9768-43ff-b3b7-c9db1b63745c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_5dedfed9-1575-446a-8643-7b1382fe3127" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_5dedfed9-1575-446a-8643-7b1382fe3127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4dafea4e-2d79-4d59-aa70-b989bf5bcc72" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_Security12bTitle_4dafea4e-2d79-4d59-aa70-b989bf5bcc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8fbc4655-5f32-467a-815f-e158b0f5480c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_TradingSymbol_8fbc4655-5f32-467a-815f-e158b0f5480c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_33d0b52b-644d-4619-8a7a-cd90ac9178a2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_SecurityExchangeName_33d0b52b-644d-4619-8a7a-cd90ac9178a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ea4466b3-0712-4b50-b6aa-7914330f9140" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityEmergingGrowthCompany_ea4466b3-0712-4b50-b6aa-7914330f9140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_483658f6-35f5-444f-8962-a69d90c4ec78" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_EntityCentralIndexKey_483658f6-35f5-444f-8962-a69d90c4ec78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_59526395-edab-40ea-b246-b63f3de373a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbc7f3b-df56-461b-a93a-2b3b0f7df62d" xlink:to="loc_dei_AmendmentFlag_59526395-edab-40ea-b246-b63f3de373a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139998972040512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 11,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS Life Sciences Group, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8099512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Times Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">200-5278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>sls-20230511_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sls-20230511.xsd" xlink:type="simple"/>
    <context id="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2023-05-11</startDate>
            <endDate>2023-05-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF80L2ZyYWc6ZTBiYjM1Mjc2MDNiNDVlMDgyZDhiZWIyZTkxOTBmYmEvdGFibGU6NDhlOGZjN2JhNzNlNDI3Yzk5NTMzMDgwNWJlNjI2YzYvdGFibGVyYW5nZTo0OGU4ZmM3YmE3M2U0MjdjOTk1MzMwODA1YmU2MjZjNl8xLTEtMS0xLTU2OTU3_9faf464b-1a18-4fc3-893b-84d35778f004">0001390478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF80L2ZyYWc6ZTBiYjM1Mjc2MDNiNDVlMDgyZDhiZWIyZTkxOTBmYmEvdGFibGU6NDhlOGZjN2JhNzNlNDI3Yzk5NTMzMDgwNWJlNjI2YzYvdGFibGVyYW5nZTo0OGU4ZmM3YmE3M2U0MjdjOTk1MzMwODA1YmU2MjZjNl8yLTEtMS0xLTU2OTU3_5969b188-4bc8-47b2-8efc-ef0816052637">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODEy_c075c3ec-be7f-4f41-9656-958e3df2f8f4">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yMzQ_77cb147d-948e-4716-9aa3-1ec22d19ff35">2023-05-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODEz_78180409-6cfc-4201-80a0-515de5e37780">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18wLTAtMS0xLTU2OTU3_73c1c18a-d8ed-425f-9962-767fa552d625">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18wLTItMS0xLTU2OTU3_5e0073bb-f658-4f9e-86b3-0a956cfc3dd4">001-33958</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18wLTQtMS0xLTU2OTU3_81995cc7-d64c-47ea-afce-2492ec75b11a">20-8099512</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfNQ_91abcf4c-3619-442c-a2a8-ae258707d4d2">7 Times Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfOQ_290e2f26-dab6-4be8-bf5f-a9afc1885d8c">Suite 2503</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfMTI_9d927d60-57a2-4d86-a4eb-395f37d3c98a">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfMTY_82492b20-a4d3-42b8-9bca-8820a3259f44">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y18zLTItMS0xLTU2OTU3L3RleHRyZWdpb246ZDBiMzQ0Mzg0NGE1NGQxYWFlMDc0MWM2N2IyM2M1NmJfMTk_46370a03-8705-43bc-8115-130458c2e797">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y182LTAtMS0xLTU2OTU3L3RleHRyZWdpb246NDU2NmE0YWQ1OTkzNDVkMzliM2JmNWUzZjJmNmFlY2ZfNTY_e8f491c4-501a-4c13-af1b-f9bd8b40a207">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6Y2FkOWEzNTU0ZDYxNGYxYTk4NmIwODg4YTllM2Q2OWMvdGFibGVyYW5nZTpjYWQ5YTM1NTRkNjE0ZjFhOTg2YjA4ODhhOWUzZDY5Y182LTAtMS0xLTU2OTU3L3RleHRyZWdpb246NDU2NmE0YWQ1OTkzNDVkMzliM2JmNWUzZjJmNmFlY2ZfNTk_169e8703-6533-4fb2-902e-43726dcc56b7">200-5278</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODE3_a7444ee9-c0de-4e06-a0c1-9558d4c6730a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODE5_04cf3cbf-e040-4aae-ad75-3be0eca60f3a">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODIx_9e30fab0-186f-4ed8-a6a2-f8c824f12652">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODE1_62a53652-fd02-4739-98e6-1820e7847e87">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6YzdjN2ZmZWU3ZGU2NDliM2JmNmJiZmE1OGI3MWRmYmYvdGFibGVyYW5nZTpjN2M3ZmZlZTdkZTY0OWIzYmY2YmJmYTU4YjcxZGZiZl8xLTAtMS0xLTU2OTU3_8a87491e-edb8-4ee9-98fd-7178a1c5020f">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6YzdjN2ZmZWU3ZGU2NDliM2JmNmJiZmE1OGI3MWRmYmYvdGFibGVyYW5nZTpjN2M3ZmZlZTdkZTY0OWIzYmY2YmJmYTU4YjcxZGZiZl8xLTEtMS0xLTU2OTU3_67aa85da-0fd1-4761-be5f-91a27e9e6d8b">SLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGFibGU6YzdjN2ZmZWU3ZGU2NDliM2JmNmJiZmE1OGI3MWRmYmYvdGFibGVyYW5nZTpjN2M3ZmZlZTdkZTY0OWIzYmY2YmJmYTU4YjcxZGZiZl8xLTItMS0xLTU2OTU3_424e22a8-f4c6-40b4-adf1-b15148ab51ee">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkMTcwMzFiMTRhOTRmZTk5ZGM0MjI3OWE1YzNhOWI4L3NlYzoyZDE3MDMxYjE0YTk0ZmU5OWRjNDIyNzlhNWMzYTliOF8xL2ZyYWc6MjNiMGVhNGExNGU3NGJjYjlhZDIzN2E5MTAyMmRlM2UvdGV4dHJlZ2lvbjoyM2IwZWE0YTE0ZTc0YmNiOWFkMjM3YTkxMDIyZGUzZV8yODE2_c4fad4d5-7d02-41f9-bab8-34062f2cab9f">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  J"JU8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  *@JM6T1&O".X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TEQ#Z';B^))07!!\1:2V=U@TX9DI-VW-XV[740?P&-F_GSS
M#4QK@C)CQ.<X!HSD,-W,OA^2,F'+CD1! 21S1*]3G1-#;N['Z#7E9SQ T.9#
M'Q DYQOP2-IJTK  J[ 26==:HTQ$36,\XZU9\>$S]@5F#6"/'@=*(&H!K%LF
MAM/<MW %+##"Z--W >U*+-4_L:4#[)R<DUM3TS354U-R>0<!;T^/+V7=R@V)
M]& P_TI.T2G@EETFOS9W][L'UDDNFXK?5D+L)%=BHR1_7UQ_^%V%_6C=WOUC
MXXM@U\*ON^B^ %!+ P04    "  *@JM6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M  J"JU9G?PYS8@0  "41   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9AO<^(V$,:_BL;M=.YFDF"+/X$4F"&$7#.7Y&A,>W/M](6P!6C.EGR2',*W
M[\J 37MFH7V#+>-]^$E:/2O17RO]U:PXM^0M3:09>"MKLYM&PT0KGC)SI3(N
MX9N%TBFST-3+ALDT9W$1E"8-ZON=1LJ$](;]XME4#_LJMXF0?*J)R=.4Z<TM
M3]1ZX 7>_L&+6*ZL>] 8]C.VY"&WOV53#:U&J1*+E$LCE"2:+P;>*+BYI6T7
M4+SQN^!K<W!/7%?F2GUUC8=XX/F.B"<\LDZ"P>65CWF2."7@^+83]<K?=(&'
M]WOU^Z+ST)DY,WRLDL\BMJN!U_5(S!<L3^R+6O_"=QTJ ".5F.*3K+?OMEH>
MB7)C5;H+!H)4R.V5O>T&XC" '@F@NP!:<&]_J*"\8Y8-^UJMB79O@YJ[*;I:
M1 .<D&Y60JOA6P%Q=CA6KUSW&Q:DW(-&M N[W8;1(V%/;$."X()0GS;_&=T
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ "H*K5JK$(A8S 0  (@(   \
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M4$L! A0#%     @ "H*K5M$1KPCN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ "H*K5IE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  *@JM69W\.<V($   E$0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ "H*K5I^@&_"Q @  X@P
M  T              ( !I0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  *
M@JM6EXJ[',     3 @  "P              @ &!#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  *@JM6JL0B%C,!   B @  #P              @ %J$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "H*K5B0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ "H*K5F60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sls-20230511.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="sls-20230511.htm">sls-20230511.htm</File>
    <File>sls-20230511.xsd</File>
    <File>sls-202305118xkexhibit991.htm</File>
    <File>sls-20230511_lab.xml</File>
    <File>sls-20230511_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sls-20230511.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "sls-20230511.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sls-20230511_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sls-20230511_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sls-20230511.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "sls",
   "nsuri": "http://www.sellaslifesciences.com/20230511",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20230511.htm",
      "contextRef": "i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.sellaslifesciences.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20230511.htm",
      "contextRef": "i5f3bd97c2d16487fa99e22493f96928a_D20230511-20230511",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001390478-23-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-23-000013-xbrl.zip
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MAR'/0-2)D;.:X+%#<*:@=0"DO>.E:$.UT.Y>,ZL)M%6$VA_6+/<(RQV"FO(
MB?W3&DA/$*'AFM]F^,TX473/USS7QUS1%:Q3RC%EEH$UERO<HZ;B:^^%WV[6
M&_7R!;^'V52=8I7<XK?*R.O2_BF?PVVZ4LRJKQGN,8;[%G.AW\09,WE]B[!!
MXH;O"W]DS7BW&:\Z.G&XIOC458 63!\4';,Q-2G!ONW91/=58AKDG3 >K#OV
M;BW\8AI/U1DF&^Z')[!AUF#-B$]DQ&J2#'F\9L?[]:!Z8A)J:,!RV&<*P;JE
M.=BQN0D$0A1NV;H%SOVOS8X:F-L;WA/8,6^P,#MJK^!(WS*D,Y^6Q^ 6W\8
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M5^[15_M,1#(X<L?(D]OD -,YF)A<'C">V;T.$@3 <9CGJ;#J3^/H,NV*@,A
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MO;VZL]>KU6K[CK,GNO]GPR:WX')]3YP,/?'O=[X,*@.!SS]HUL/D\$:ZR>#
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MG]OXG1%TK)=&*"Q9/Y4N K]J.*/44NHHJN;,6I!)ANTN 0_(_*K[MS8NM;@
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MS!$04WF;[*ZN2A+E']1&MX"24%Z:3-]R2ZI'__\@&DF>OJAT@="N*KP'!'+
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M*YT"#:8 3Y6Y8(Q&7FKZR:O@\N9 BJZKKH=-!J;MT@S)Q)8#;'41ABJ'B[9
M=?D]M!XG(&"Q -SY@IUFC2M<B^98]+7MA_@=$RZP!XUO1T9.ZL<T4B?6]:7B
M)]@$IK$@/R8OX#M9##5*)"&\RFT&GE /" "BC?:4DRPIGC,OO/UR6_@8I8X
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M!9<E6W]K=EBSPQ./R5D*.\Q^=VVVY7*\@W:KJ]PA_#-(?.^W_P=02P,$%
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M]#;EU>< J_B^4\(YO_NHS/R2Q,EJ_^33S94PJT4J)6$84R"(,',"\@5@7"&
M6,Q0B!F$L;4O[QQIHI."0>LUX7HKO*YS0A?!MI/" 6@;9U9P9ZS'I+"'C0&S
M0E?FD:>%/05NSPO[#G"?&+YI>9.;S!")\Z18Z+E6G"C(* CB4 (2X0!$FH4
M^XP(J8/8%X'M7/ T^=3D7X'RLMB#Z!_BG]X&KKWJM]C;+_0AG!Q9VZYT.$FZ
MJ^Y>*MY*-IIPN\JH:[4SIJ]O?T@6>F/5 6)$"0@HBR) .#17SW[L@RA T%<P
M-)8=N5GU8_*IR7/M-27 GGY<(\[6@OO1,8[KVC#1PV>W2QY@K;5D([OI=AG;
M!MH2XR[*'T;<A4[+W;*;=&W$R[D. @(QPB D/  D)"&(0L8 H['/J RB6%A?
M6+>.,#5YKD%Z393V$FVG<;].!Y-S9+$Z\N(DV)VU]U)M>\;1I+NSH+I^=P>Z
MB_C)=O?'Y?)&Y_46BJ""(Y\KL_*5YJ(X(@((&(> 1BC0L:*<V&]6[QML:M+>
MZKNL$!^F3[5-M7.W:A"!8_>L7+@;TKKJ).40#:SMY,_5QNHL<T<SJ_N8ODOR
M]U<ZOTC2B]_S[+:X-&-=\_1^'F$F DABX*-0F=4YDH K3 &#.%!"0,DH<EN=
MMXXSM>EBO3S=8/568+TU6M=%>SNUMNOWP82-LY1WY:K'LGXG$P-6^.UY1U[L
M[RQN>]V_.]Q]$CC/>7F3Y[?[*Y$MY@ISC4,< "/P&!"%8\!CWP>28H9IQ(04
MV%;VC<Q3$_H:G+="9R_L)EW[I=R;A&/OD-G5[R36UEI[R;.9:31!MA90EV![
M@+OH-G=//]PR^!LO]%P*Z@?<B$_X#!O/%1((*F, S1)=*88Q#Z6M^%I'F)H(
M'VXB7Z'T#$ROQ&DOQW8B]\MR,#U'EJ<S,TY"W5E]+\&V9QQ-N#L+J@MX=V"/
MIE.V2&12F#GA#Y,H3_AB3K4O&(4:4*E"8Z$T )'T!8"(($6(]&FHK=M.6^FG
M)N%'A-X&HD/3:9L]B[;3($Z.K%L7.MR:3IU5]VL[;:<;K_'464JC]=0=U=]O
MS\VA<R@51X%/011! 8B( L"EB@")>.!KPQ*3U-5FR\13D^:#AY3@W"VUXLK>
M25T9&,M =Q;?RS7KE0XRRRK1Z!Y9A]]FC8W/W:5V6M[TE6M^FBD]Q^9R,:22
M 0T)*W>1%! \#H ,&#-2,X:(K'>>ZXFG)K73ZOY" \XKT=EKK4'6?JWUI>#(
M6K.LWDEL;:7V$ELCT6AB:X-?%UOKYWUW<#^F,LNOL[SJ)%5W6IYF-VF1WU>G
ME;EH1!C'$"C".2!:F?6H3\Q%)D&<^ 0*BAQOD]XYWM2DN=ZE;&"NW0*\1NZH
M6QO>;;=Y#\;F.-N]@XCLL?=K1<^ />#=^4?>"[8J=GM/V.ZP@8]?K/\[2U(-
MYY#*R \$!PP1"(C/,>#<7.1JA$.%B1]II'H]>U$?9:)3R<-S!.L77@G6^YSV
M?>ZB0:SMK#&0KG'F"G>F^C]PT<;$\*<M&EF?YU&+ML(ZG[-H#>XK_*_Z(ED6
M.4^+3^:[GD<JT$+A " A,2"$8""0)B!&84!X$&D:,#?--P>8J-P?07HE2E>1
M/R'15M_]J1E'VK:L]!!T>^D#M/PDX<@R;B]G6\$=<8=S;30G&I&0(@Q4@"4@
MB$%@K@X(P)0Q3K@Q;V3=8.H<9:(R;O>B\]MLN&NC :[M1-=SNO8NI@[BVN@H
MKHV>W[61BVNC <(O?TMJ\>4R2S=/"AA1"QB$# @:1(! 7P,1!P1 &'#*!)3$
MMVY%/4T^-9E7^+P*H/,C%EO$[=?S$#J.+&,')IR$VU5R+[UN)1M-IEUEU-79
M&3/0C<MMO\_Y>7:;SOT@$C ..$!2AF8UK12(8B$!X@IB3H4([+79,<;4)/K4
M7ZI]XRSW2JP]7;A&J*,']Z-I9 >V8JB_^VYS,-Q[:SF?QWFWB^KTW9;0'@VO
M[*?.WXERZ2X+FR9./7Y"YUZ%R_OO!MG_#M3'::NV7R.GD6F\3DY; 8U63FO
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MOQ/[K_X-4$L! A0#%     @ "H*K5AP1C5EW%0  L*$  !
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L  !S;',M,C R,S U,3%?<')E+GAM;%!+!08     !0 % $L!   F20     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
